Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-322 plus pioglitazone versus SYR-322 alone or pioglitazone alone in type 2 diabetes
2006-005492-17Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing SYR-322 + pioglitazone hydrochloride, SYR-322 monotherapy and Pioglitazone hydrochloride monotherapy (3 arms). Primary endpoint: Change from baseline in HbA1c at Week 26. Started Nov 2006; status: completed.
02
Drugs
alogliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-005492-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005492-17.